Peer-Reviewed Publications

      BELIEF - a semiautomatic workflow for BEL network creation

      Fluck, J.; Madan, S.; Ansari, S.; Szostak, J.; Hoeng, J.; Zimmermann, M.; Hofmann-Apitius, M.; Peitsch, M. C.
      Published
      Oct 6, 2014
      Link to publication
      Topic
      Summary

      In order to build networks for systems biology from the literature an UIMA based extraction workflow using various named entity recognition processes and different relation extraction methods has been composed. The Unstructured Information Management architecture (UIMA) is a Java-based framework that allows assembling complicated workflows from a set of NLP components. The new system is processing scientific articles and is writing the open-access biological expression language (BEL) as output. BEL is a machine and human readable language with defined knowledge statements that can be used for knowledge representation, causal reasoning, and hypothesis generation. In order to curate the automatically derived BEL statements, our workflow integrates a curation interface that provides access to BEL statements generated by text mining and that integrates supporting information to facilitate manual curation. By using the semi-automated curation pipeline, expert time to model relevant causal relationships in BEL could be significantly reduced. In this paper the UIMA workflow and key features of the curation interface are described.

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.